Circulating Biomarkers in Hypertrophic Cardiomyopathy

Figures

• 

  Figure 1. Circulating biomarkers in hypertrophic cardiomyopathy that correlate with noninvasive imaging include NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), cTnI (cardiac troponin I), hs‐cTnT (high‐sensitivity cardiac troponin T), and hs‐cTnI (high‐sensitivity cardiac troponin I). LA indicates left atrium; LGE, late gadolinium enhancement; LV, left ventricle; and LVOT, left ventricular outflow tract.

• 

  Figure 2. Circulating biomarkers in hypertrophic cardiomyopathy that correlate with clinical outcomes include brain natriuretic peptide (BNP), NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), galectin‐3, uric acid, and hs‐cTnT (high‐sensitivity cardiac troponin T). MACE definitions: congestive heart failure, arrhythmia, death (references [56, 78]); congestive heart failure‐related death, hospitalization, NYHA progression; arrhythmia‐related sudden cardiac death, ventricular tachycardia, appropriate implantable cardioverter defibrillator discharge (reference [36]); sudden cardiac death; heart failure‐related death, stroke‐related death; heart failure hospitalization, stroke hospitalization, ventricular tachycardia, appropriate implantable cardioverter defibrillator discharge, worsening NYHA class (reference [40]). BP indicates blood pressure; LV, left ventricle; MACE, major adverse cardiac events; and NYHA, New York Heart Association.